The Medical device market is growing with evolving needs of patients and with their emerging diseases encouraging them to develop novel and innovative therapies or devices for maintaining quality of life. The ledger for 2019 of medical devices has shown changes for multiple companies but the position for Medtronic remains same to be one top […]Read More
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma Our team at PharmaShots […]Read More
The global biopharma companies are developing novel therapies & devices which is, in turn, enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies’ chartbusters changed their 2019 ranking, but the history of Johnson and Johnson did not change and it continued being at the […]Read More
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. This first part is […]Read More
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. The companies are focusing on […]Read More
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More
The global generics pharmaceutical market is continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs, are always needed in the market. Generics are approved copies of small molecule drugs which contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of […]Read More
Healthcare, pharmaceutical, and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda’s acquisition of Shire for $57B with the focus on global R&D, its robust and modality-diverse […]Read More
The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
